Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K. drugmaker reported adjusted EPS of $2.38, well above the $1.13 consensus, while revenue rose 11.9% year-over-year to $15.19B, topping estimates by $420M.
Oncology product sales
Ever thought about bringing your mom or dad to an interview with you? Well, it’s a bad look—at least according...
Gasoline prices rose to just under $3 on Monday as oil prices surged amid a widening Middle East war. The...
Israeli startup Gloat is laying off 20% of its employees, "Globes" has learned. According to sources familiar with the...
Selenis is set to expand its industrial headquarters in Portalegre, Portugal, aiming to double the site’s production capacity by the...
As Israel unleashed a sweeping military response to the brutal Oct. 7, 2023, assault by Hamas, it aimed punch after punch...
In the midst of the war with Iran and Lebanon, advanced gunsights developer and producer Smart Shooter has raised...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
